Satsuma backs away from commercial efforts after migraine candidate fails to hit primary endpoint

Two years ago, Satsuma Pharmaceuticals had a Phase III failure for a nasal drug intended to treat migraines, and now it seems the company has hit another roadblock.

According to the South San Francisco biotech on Monday, its candidate STS101, a nasal powder intended to treat migraines, did not achieve...

Click to view original post